Documents
Resources
Learning Center
Upload
Plans & pricing Sign in
Sign Out

Aradigm Corporation (ARDM) - Financial and Strategic Analysis Review

VIEWS: 22 PAGES: 34

Aradigm Corporation (Aradigm) is a specialty pharmaceutical company engaged in the development and commercialization of drugs delivered by inhalation for treating severe respiratory diseases by pulmonologists. It has developed pulmonary drug delivery system, AERx Essence and AERx Strip Technology for the delivery of drugs to the target. The company's current pipeline comprises of products used for treating cystic fibrosis, inhalation anthrax and bronchiectasis. Its research and development activity consisted of collaborative and contracted research on the pipeline products and existing products in the market. Aradigm Corporation Key Recent Developments May 13, 2010 Aradigm Reports Net Loss Of $0.2 Million For Q1 2010 Mar 23, 2010 Aradigm Posts Net Loss Of $3.4 Million In Q4 2009 Feb 23, 2010 Aradigm Doses First Patient In Second Phase 2b Clinical Trial Of Ciprofloxacin Feb 04, 2010 Aradigm Receives Milestone Payment From Zogenix Aug 06, 2009 Aradigm Reports Net Loss Of $4.6 Million In Q2 2009 This comprehensive SWOT profile of Aradigm Corporation provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. The profile contains critical company information including, - Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy – Analyst’s summarization of the company’s business strategy. - SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats. - Company history – Progression of key events associated with the company. - Major products and services – A list of major products, services

More Info
									       Aradigm Corporation (ARDM) - Financial and Strategic Analysis Review

       Reference Code: GDME1294FSA                                                                                      Publication Date: AUG 2010

       3929 Point Eden Way                    Phone            +1 510 2659000                           Revenue           4.9 (million USD)
       Hayward, CA                            Fax              +1 510 2650277                           Net Profit        -13.77 (million USD)
       94545                                  Website          www.aradigm.com                          Employees         15
       United States                          Exchange         ARDM [Over The Counter]                  Industry          Medical Equipment

      Company Overview
       Aradigm Corporation (Aradigm) is a specialty pharmaceutical company engaged in the development and commercialization of
       drugs delivered by inhalation for treating severe respiratory diseases by pulmonologists. It has developed pulmonary drug
       delivery system, AERx Essence and AERx Strip Technology for the delivery of drugs to the target. The company's current
       pipeline comprises of products used for treating cystic fibrosis, inhalation anthrax and bronchiectasis. Its research and
       development activity consisted of collaborative and contracted research on the pipeline products and existing products in the
       market.

      Key Executives                                                                 SWOT Analysis
                    Name                                   Title                     Aradigm Corporation, SWOT Analysis
      Igor Gonda, Ph.D.                     Chief Executive Officer                  Strengths                 Weaknesses

      Virgil D. Thompson                    Chairman
                                                                                                                        Dependence on Contract
      Frank H. Barker                       Director                                 Intellectual Property Rights       Manufacturers
      Dr. John M. Siebert                   Director
                                                                                     Strong Liquidity Position          Limited Operating Margin
      Nancy Pecota                          Chief Financial Officer
      Source: Annual Report, Company Website, Primary and Secondary Research
      GlobalData
                                                                                     Opportunities                      Threats
      Share Data
      Aradigm Corporation                                                            Rising Healthcare                  Uncertain R&D Outcomes
       Share Price (USD) as on 25-Aug-2010                                 0.20      Expenditure in the US

                                                                          -0.15                                         Competitive Market
       EPS (USD)
                                                                                     Pipeline Products
       Market Cap (million USD)                                                 22

       Enterprise Value (million USD)                                           21

       Shares Outstanding (million)                                         138      Source: Annual Report, Company Website, Primary and Secondary Research
       Source: Annual Report, Company Website, Primary and Secondary Research        GlobalData
       GlobalData

      Financial Performance                           
								
To top